NASDAQ · OPNT
Healthcare · Biotechnology
$20.65
Up+$0.00 (+0.00%)
Updated Sep 11, 2026, 11:39 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
OPNT does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning OPNT.
OPNT research
Company profile and research snapshot.
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 9, 2021 | Oppenheimer | Outperform | — |
| Sep 28, 2018 | Cantor Fitzgerald | Overweight | — |
| Jun 12, 2018 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Feb 7, 2023
SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV).
GlobeNewswire Inc. · Jan 19, 2023
SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for OPNT003, nasal nalmefene, Opiant’s product candidate for the treatment of opioid overdose.
GlobeNewswire Inc. · Nov 22, 2022
SANTA MONICA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has completed submission of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for OPNT003, nasal nalmefene, for the treatment of opioid overdose.
Benzinga · Nov 15, 2022
Major Wall Street indices closed in the red on Monday, in a reversal of last week’s rally driven by softer inflation data. On Sunday, Federal Reserve Governor Christopher Waller said markets should pay attention to the "endpoint" of rate increases, not the pace of each move, and that the endpoint is likely still "a ways off." The indices pared some of their losses after Federal Reserve Vice Chair Lael Brainard indicated the central bank may soon slow the pace of its interest rate increases. Meanwhile, here are the five stocks that are drawing retail investors’ attention today: 1. Tesla Inc (NASDAQ: TSLA): Elon Musk’s $56 billion pay granted by Tesla is being contested in court, reported BBC News. ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OPNT.
No results
No recent SID articles mention OPNT.
